Wedbush Securities Sees Preparations Continuing For Expected Approval And Strong Launch Of Kanuma For Synageva Biopharma
February 27, 2015 at 10:34 AM EST
In a report published Friday, Wedbush Securities analyst David M. Nierengarten reiterated an Outperform rating and $111.00 price target ...
